COPD in a Nationally Representative Sample: Sociodemographic Factors and Co-morbidity, Diagnosis Method, and Healthcare Utilization

References

• Murray CJ, Lopez AD. Mortality by cause for eight regions of the world: Global Burden of Disease Study. Lancet 1997; 349:1269–1276.
   PubMed Web of Science ®Google Scholar
• Murray CJ, Lopez AD. Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study. Lancet 1997; 349:1498-1504.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Behavioral Risk Factor Surveillance System 2012. 2012. Available at: http://www.cdc.gov/brfss/
   Google Scholar
• Centers for Disease Control and Prevention. Behavioral Risk Factor Surveillance System, 2003 Summary Data Quality Report. 2004.
   Google Scholar
• SAS Institute Inc. 2012. Cary, NC, USA.
   Google Scholar
• Li C, Balluz LS, Ford ES, Okoro CA, Zhao G, Pierannunzi C. A comparison of prevalence estimates for selected health indicators and chronic diseases or conditions from the Behavioral Risk Factor Surveillance System, the National Health Interview Survey, and the National Health and Nutrition Examination Survey, 2007–2008. Prev Med 2012; 54:381–387.
   PubMed Web of Science ®Google Scholar
• GOLD. Global strategy for the diagnosis, managemebnt, and prevention of chronic obstructive pulmonary disease. 2012. Available at: http://www.goldcopd.org/
   Google Scholar
• Fabbri LM, Romagnoli M, Corbetta L, Casoni G, Busljetic K, Turato G, et al. Difference in airway inflammation in patients with fixed airflow obstruction due to asthma or chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2003; 167:418–424.
   PubMed Web of Science ®Google Scholar
• Shaya FT, Dongyi D, Akazawa MO, Blanchette CM, Wang J, Mapel DW, et al. Burden of concomitant asthma and COPD in a Medicaid population Chest 2008; 134:14–19.
   Google Scholar
• Soriano JB, Davis KJ, Coleman B, Visick G, Mannino D, Pride NB. The proportional Venn Diagram of obstructive lung diseases: two approximations from the United States and the United Kingdom. Chest 2003; 124:474–481.
   PubMed Web of Science ®Google Scholar
• de Marco R, Pesce G, Marcon A, Accordini S, Antonicelli L, Bugiani M, et al. The coexistence of asthma and chronic obstructive pulmonary disease (COPD): prevalence and risk factors in young, middle-aged and elderly people from the general population. PlosOne 2013; 8:e62985.
   PubMed Web of Science ®Google Scholar
• Behrendt CE. Mild and moderate –to-severe COPD in nonsmokers: distinct demographic profiles. Chest 2005; 128:1239–1244.
   PubMed Web of Science ®Google Scholar
• Lamprecht B, McBurnie MA, Vollmer WM, Gudmundsson G, Welte T, Nizankowska-Mogilnicka E, et al. Chest 2011; 139:752–763.
   PubMed Web of Science ®Google Scholar
• Menezes AM, Perez-Padilla R, Jardim JR, Muino A, Lopez MV, Valdivia G, et al. Chronic obstructive pulmonary disease in five Latin American cities (the PLATINO study): a prevalence study. Lancet 2005; 366:1875–1881.
   PubMed Web of Science ®Google Scholar
• Zhou Y, Wang C, Yao W, Chen P, Kang J, Huang S, Chen B, Wang C, Ni D, Wang X, et al. COPD in Chinese nonsmokers. Eur Respir J 2009; 33:509–518.
   PubMed Web of Science ®Google Scholar
• Zahran HS, Bailey V. Factors Associated with Asthma Prevalence among Racial and Ethnic Groups-United States, 2009–2010 Behavioral Risk Factor Surveillance System. J Asthma 2013; 50:583–589.
   PubMed Web of Science ®Google Scholar
• Zahran HS, Person CJ, Bailey C, Moorman JE. Predictors of asthma self-management education among children and adults–2006-2007 behavioral risk factor surveillance system asthma call-back survey. J Asthma 2012; 49:98–106.
   PubMed Web of Science ®Google Scholar
• Pierannunzi C, Hu SS, Balluz L. A systematic review of publications assessing reliability and validity of the Behavioral Risk Factor Surveillance System (BRFSS), 2004–2011. BMC Med Res Methodol 2013; 13:49.
   PubMed Web of Science ®Google Scholar
• Anzueto A, Ferguson GT, Feldman G, Chinsky K, Seibert A, Emmett A, Knobil K, O'Dell D, Kalberg C, Crater G. Effect of fluticasone propionate/salmeterol (250/50) on COPD exacerbations and impact on patient outcomes. COPD 2009; 6:320–329.
   PubMedGoogle Scholar
• Calverley PM, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW, Yates JC, Vestbo J. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007; 356:775–789.
   PubMed Web of Science ®Google Scholar
• Drummond MB, Dasenbrook EC, Pitz MW, Murphy DJ, Fan E. Inhaled corticosteroids in patients with stable chronic obstructive pulmonary disease: a systematic review and meta-analysis. JAMA 2008; 300:2407–2416.
   PubMed Web of Science ®Google Scholar
• Ernst P, Gonzalez AV, Brassard P, Suissa S. Inhaled corticosteroid use in chronic obstructive pulmonary disease and the risk of hospitalization for pneumonia. Am J Respir Crit Care Med 2007; 176:162–166.
   PubMed Web of Science ®Google Scholar
• Ferguson GT, Anzueto A, Fei R, Emmett A, Knobil K, Kalberg C. Effect of fluticasone propionate/salmeterol (250/50 microg) or salmeterol (50 microg) on COPD exacerbations. Respir Med 2008; 102:1099–1108.
   PubMed Web of Science ®Google Scholar
• Kardos P, Wencker M, Glaab T, Vogelmeier C. Impact of salmeterol/fluticasone propionate versus salmeterol on exacerbations in severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007; 175:144–149.
   PubMed Web of Science ®Google Scholar
• Lee TA, Weiss KB. Fracture risk associated with inhaled corticosteroid use in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2004; 169:855–859.
   PubMed Web of Science ®Google Scholar
• Singh S, Loke YK, Furberg CD. Inhaled anticholinergics and risk of major adverse cardiovascular events in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. JAMA 2008; 300:1439–1450.
   PubMed Web of Science ®Google Scholar
• Miravitlles M, Ferrer M, Pont A, Zalacain R, Alvarez-Sala JL, Masa F, Verea H, Murio C, Ros F, Vidal R. Effect of exacerbations on quality of life in patients with chronic obstructive pulmonary disease: a 2 year follow up study. Thorax 2004; 59:387–395.
   PubMed Web of Science ®Google Scholar
• Calverley PM, Boonsawat W, Cseke Z, Zhong N, Peterson S, Olsson H. Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. Eur Respir J 2003; 22:912–919.
   PubMed Web of Science ®Google Scholar
• Vestbo J. The TORCH (towards a revolution in COPD health) survival study protocol. Eur Respir J 2004; 24:206–210.
   PubMed Web of Science ®Google Scholar
• Joo MJ, LeeTA, Au DH, Fitzgibbon ML, Weiss KB. Medication use patterns associated with spirometry in diagnosing COPD. COPD 2008; 5:360–368.
   PubMedGoogle Scholar
• Chavannes N, Schermer T, Akkermans R, Jacobs JE, van de Graaf G, Bollen R, Van SO, Bottema B. Impact of spirometry on GPs’ diagnostic differentiation and decision-making. Respir Med 2004; 98:1124–1130.
   PubMed Web of Science ®Google Scholar
• Dales RE, Vandemheen KL, Clinch J, Aaron SD. Spirometry in the primary care setting: influence on clinical diagnosis and management of airflow obstruction. Chest 2005; 128:2443–2447.
   PubMed Web of Science ®Google Scholar
• Walker PP, Mitchell P, Diamantea F, Warburton CJ, Davies L. Effect of primary-care spirometry on the diagnosis and management of COPD. Eur Respir J 2006; 28:945–952.
   PubMed Web of Science ®Google Scholar
• Yawn BP, Enright PL, Lemanske, Jr. RF, Israel E, Pace W, Wollan P, Boushey H. Spirometry can be done in family physicians’ offices and alters clinical decisions in management of asthma and COPD. Chest 2007; 132:1162–1168.
   PubMed Web of Science ®Google Scholar
• Mathers C, Boerma T, Ma Fat D. Global Burden of Disease 2004. World Health Organization. 2004; 6-2-2012. http://www.who.int/healthinfo/global_burden_disease/GBD_report_2004update_full.pdf
   Web of Science ®Google Scholar
• Prescott E, Lange P, Vestbo J. Socioeconomic status, lung function and admission to hospital for COPD: results from the Copenhagen City Heart Study. Eur Respir J 1999; 13:1109–1114.
   PubMed Web of Science ®Google Scholar
• Elixhauser A, Au DH, Podulka J. 2006. Readmissions for Chronic Obstructive Pulmonary Disease, 2008: Statistical Brief #121.
   Google Scholar
• American Lung Association. Trends in COPD (Chronic Bronchitis and Emphysema): Morbidity and Mortality. 2013. Available at: http://www.lung.org/finding-cures/our-research/trend-reports/copd-trend-report.pdf. Accessed: 06/27/2014
   Google Scholar
• Mannino DM, Homa DM, Akinbami LJ, Ford ES, Redd SC. Chronic obstructive pulmonary disease surveillance–United States, 1971-2000. Respir Care 2002; 47:1184–1199.
   PubMedGoogle Scholar
• Blair IV, Havranek EP, Price DW, Hanratty R, Fairclough DL, Farley T, Hirsh HK, Steiner JF. Assessment of biases against Latinos and African Americans among primary care providers and community members. Am J Public Health 2013; 103:92–98.
   PubMed Web of Science ®Google Scholar
• Straus SE, McAlister FA, Sackett DL, Deeks JJ. The accuracy of patient history, wheezing, and laryngeal measurements in diagnosing obstructive airway disease. CARE-COAD1 Group. Clinical Assessment of the Reliability of the Examination-Chronic Obstructive Airways Disease. JAMA 2000; 283:1853–1857.
   PubMed Web of Science ®Google Scholar
• Straus SE, McAlister FA, Sackett DL, Deeks JJ. Accuracy of history, wheezing, and forced expiratory time in the diagnosis of chronic obstructive pulmonary disease. J Gen Intern Med 2002; 17:684–688.
   PubMed Web of Science ®Google Scholar